APPLICATION OF HYPERPOLARIZED XENON-129 VIA THE VASCULAR SYSTEM

通过血管系统应用超极化 XENON-129

基本信息

  • 批准号:
    8171568
  • 负责人:
  • 金额:
    $ 1.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. During the past decade, hyperpolarized (HP) 129Xe has found application in biomedical MRI with exciting results. Typically, the gas is introduced into the organism by inhalation, which is an efficient strategy for imaging the gas space of the lungs. Due to the alveolar gas exchange, a small amount of inhaled HP 129Xe enters the pulmonary blood and is delivered to other organs. This has already been exploited to study brain perfusion. More efficient methods for the local delivery of xenon to other target organs may include pre-dissolving of the HP gas in a suitable liquid or the production of microbubbles with subsequent injection into the blood stream. For initial experiments, we will use isotopically enriched 129Xe (82%), Intralipid 30% (Pharmacia, Clayton, NC) and a 'shaker' as described in M¿ller et al. MRM 41, 1058 (1999) to reproduce previous experiments serving as a reference. The search for other vehicles for local delivery will include dissolving of HP 129Xe in fully oxygenated blood or plasma and dissolving of HP 129Xe in deuterated saline solution. Although the solubility of xenon in these liquids is significantly less than that of lipid emulsions, they are of interest because Xe will be released to the alveolar gas phase upon passing through the lungs, which can be exploited for perfusion imaging if RF excitation is selectively applied to the gas phase resonance. In addition, such systems may be tolerated better during prolonged infusion experiments. Experiments with deuterated saline are of further interest one may expect a drasticallyprolonged 129Xe T1. Insead of the previously used 'shaker' for dissolving HP 129Xe, another strategy will involve hollow-fiber membranes to improve the process of dissolving. This technique may also hold a potential for continuous infusion of the HP gas carrier. For comparison, experiments involving direct injection of small amounts of HP 129Xe into a vein will also be investigated. Regarding the Ostwald solubility (L) of Xe in water, roughly 0.1 mL of gas may be injected per mL of blood. If f is the venous blood flow in mL/sec, HP gas may be injected continuously at a rate of L x f provided that the dissolving process is sufficently rapid in vivo and the gas is quantitatively released to the alveoli.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 在过去的十年中,超极化(HP)129已在生物医学MRI中得到应用,并取得了令人兴奋的结果。通常,通过吸入将气体引入生物体中,这是用于对肺的气体空间进行成像的有效策略。由于肺泡气体交换,少量吸入的HP 129进入肺血并输送到其他器官。这已经被用来研究脑灌注。将氙局部输送到其他目标器官的更有效方法可能包括将HP气体预溶解在合适的液体中或产生微泡并随后注射到血流中。对于初始实验,我们将使用同位素富集的129氚(82%)、Intradecid 30%(Pharmacia,克莱顿,NC)和如M ller等人,MRM 41,1058(1999)中所述的“振荡器”,以再现用作参考的先前实验。寻找用于局部递送的其他载体将包括将HP 129 β溶解在完全氧合的血液或血浆中以及将HP 129 β溶解在氘代盐溶液中。虽然氙在这些液体中的溶解度显著低于脂肪乳剂,但它们是令人感兴趣的,因为氙在通过肺时将释放到肺泡气相,如果将RF激励选择性地应用于气相共振,则可以将其用于灌注成像。此外,在延长的输注实验期间,此类系统可更好地耐受。用氘代盐水进行的实验更令人感兴趣,人们可以预期129 μ T1会大大延长。 除了以前使用的“摇动器”溶解HP 129外,另一种策略将涉及中空纤维膜以改善溶解过程。该技术还可以保持HP气体载体的连续注入的潜力。 为了进行比较,还将研究涉及将少量HP 129 β直接注射到静脉中的实验。关于在水中的Ostwald溶解度(L),每mL血液可以注入大约0.1 mL气体。如果f是静脉血流量(mL/sec),则可以以L x f的速率连续注入HP气体,前提是溶解过程在体内足够快,并且气体定量释放到肺泡。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HARALD MOLLER其他文献

HARALD MOLLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HARALD MOLLER', 18)}}的其他基金

GAS INJECTION USING A SPECIAL CATHETER FOR LUNG PERFUSION IMAGING IN THE RAT
使用特殊导管进行气体注射进行大鼠肺灌注成像
  • 批准号:
    8363156
  • 财政年份:
    2011
  • 资助金额:
    $ 1.64万
  • 项目类别:
APPLICATION OF HYPERPOLARIZED XENON-129 VIA THE VASCULAR SYSTEM
通过血管系统应用超极化 XENON-129
  • 批准号:
    8363153
  • 财政年份:
    2011
  • 资助金额:
    $ 1.64万
  • 项目类别:
GAS INJECTION USING A SPECIAL CATHETER FOR LUNG PERFUSION IMAGING IN THE RAT
使用特殊导管进行气体注射进行大鼠肺灌注成像
  • 批准号:
    8171573
  • 财政年份:
    2010
  • 资助金额:
    $ 1.64万
  • 项目类别:
GAS INJECTION USING A SPECIAL CATHETER FOR LUNG PERFUSION IMAGING IN THE RAT
使用特殊导管进行气体注射进行大鼠肺灌注成像
  • 批准号:
    7956902
  • 财政年份:
    2009
  • 资助金额:
    $ 1.64万
  • 项目类别:
APPLICATION OF HYPERPOLARIZED XENON-129 VIA THE VASCULAR SYSTEM
通过血管系统应用超极化 XENON-129
  • 批准号:
    7956893
  • 财政年份:
    2009
  • 资助金额:
    $ 1.64万
  • 项目类别:
APPLICATION OF HYPERPOLARIZED XENON-129 VIA THE VASCULAR SYSTEM
通过血管系统应用超极化 XENON-129
  • 批准号:
    7726171
  • 财政年份:
    2008
  • 资助金额:
    $ 1.64万
  • 项目类别:
APPLICATION OF HYPERPOLARIZED XENON-129 VIA THE VASCULAR SYSTEM
通过血管系统应用超极化 XENON-129
  • 批准号:
    7601222
  • 财政年份:
    2007
  • 资助金额:
    $ 1.64万
  • 项目类别:
APPLICATION OF HYPERPOLARIZED XENON-129 VIA THE VASCULAR SYSTEM
通过血管系统应用超极化 XENON-129
  • 批准号:
    7358308
  • 财政年份:
    2006
  • 资助金额:
    $ 1.64万
  • 项目类别:

相似海外基金

Reverse Engineering the Alveolus: From cellular to microenvironment specification during development
对肺泡进行逆向工程:从开发过程中的细胞规范到微环境规范
  • 批准号:
    10534378
  • 财政年份:
    2022
  • 资助金额:
    $ 1.64万
  • 项目类别:
Alveolus as Incubator: Functional Genomic Dissection of the Host Response to SARS-CoV-2 Infection.
肺泡作为孵化器:宿主对 SARS-CoV-2 感染反应的功能基因组解剖。
  • 批准号:
    10245986
  • 财政年份:
    2021
  • 资助金额:
    $ 1.64万
  • 项目类别:
Reverse Engineering the Alveolus: From cellular to microenvironment specification during development
对肺泡进行逆向工程:从开发过程中的细胞规范到微环境规范
  • 批准号:
    10215602
  • 财政年份:
    2019
  • 资助金额:
    $ 1.64万
  • 项目类别:
Wnt-mediated epithelial-endothelial crosstalk in the generation and regeneration of the lung alveolus
Wnt介导的上皮-内皮串扰在肺泡生成和再生中的作用
  • 批准号:
    10326831
  • 财政年份:
    2018
  • 资助金额:
    $ 1.64万
  • 项目类别:
The influence that the influence of the different exercise length, the neuromuscular electrical stimulation (NMES) in skeletal muscle, Vitamin C intake and exercise on alveolus and cytokine
不同运动时长、骨骼肌神经肌肉电刺激(NMES)、维生素C摄入和运动对肺泡和细胞因子的影响
  • 批准号:
    18K10751
  • 财政年份:
    2018
  • 资助金额:
    $ 1.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A bovine alveolus model to replace cattle in the study of host-pathogen interactions in bovine tuberculosis
牛肺泡模型替代牛用于牛结核病宿主与病原体相互作用的研究
  • 批准号:
    NC/M002047/1
  • 财政年份:
    2016
  • 资助金额:
    $ 1.64万
  • 项目类别:
    Research Grant
Reverse Engineering the Alveolus: From cellular to microenvironment specification during development
对肺泡进行逆向工程:从开发过程中的细胞规范到微环境规范
  • 批准号:
    9223730
  • 财政年份:
    2016
  • 资助金额:
    $ 1.64万
  • 项目类别:
Bone augmentation of jaw and alveolus bone with coral block in preprosthetic surgery.
在假体前手术中用珊瑚块增强颌骨和牙槽骨。
  • 批准号:
    23592909
  • 财政年份:
    2011
  • 资助金额:
    $ 1.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
EXPRESSION AND FUNCTION OF CEACAM6 IN THE ALVEOLUS
CEACAM6 在肺泡中的表达和功能
  • 批准号:
    8054534
  • 财政年份:
    2011
  • 资助金额:
    $ 1.64万
  • 项目类别:
The novel therapeutic approach for emphysema by regeneration of microvessel and alveolus after intrapulmonary arterial administration of gelatin microspheres slowly releasing basic fibroblast growth factor(bFGF-GMS).
肺动脉内给予缓慢释放碱性成纤维细胞生长因子(bFGF-GMS)的明胶微球后,通过再生微血管和肺泡来治疗肺气肿的新方法。
  • 批准号:
    21390393
  • 财政年份:
    2009
  • 资助金额:
    $ 1.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了